All posts by imreal

EMA Identifies Leading Security Visionaries in its Annual Vendor Vision Report Created for the 2023 RSA Conference


Text: Vendor Vision 2023 Presented by EMA | Graphic: abstract image of eyeball

EMA Vendor Vision 2023

EMA is proud to share this year’s class of Vendor Visionaries. Attendees can use the Vendor Vision report to navigate through the exhibition hall maze to visit some of the industry’s top thought leaders in information security.

Enterprise Management Associates (EMA), a leading IT and data management research and consulting firm, today announced the release of its annual Vendor Vision report. Based on criteria identified by Christopher Steffen, CISSP, CISA, and managing research director covering information security, risk, and compliance management at EMA, and Ken Buckler, research director covering information security, risk, and compliance management at EMA, this report highlights the top ten preeminent security companies in their respective categories exhibiting during the 2023 RSA Conference at San Francisco’s Moscone Center from April 24 through 27.

The following companies have been named a Visionary in EMA’s Vendor Vision report for the 2023 RSA Conference:


  • Anomali
  • Armis
  • CyberGRX
  • Dynatrace
  • Elastic
  • F5
  • IBM
  • Netenrich
  • Ordr
  • Security Journey

This is the second year of EMA’s Vendor Vision report, and it will be produced for other major conferences in the future. Designed to assist conference attendees, the Vendor Vision report is a roadmap that enables one to easily find the leading vendors and solutions at an event. According to the RSA Conference, over 600 vendors will be exhibiting at this year’s conference. Navigating the show floor without some guidance can result in missing some of the leading vendors.

“EMA is proud to share this year’s class of Vendor Visionaries,” said Steffen. “Attendees can use the Vendor Vision report to navigate through the exhibition hall maze to visit some of the industry’s top thought leaders in information security.”

A free copy of the Vendor Vision report is available on the EMA website. Additionality, each of the winners listed on the report will have copies of the report available on their respective websites.

About EMA

Founded in 1996, EMA is a leading industry analyst firm that specializes in providing deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help their clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals, and IT vendors at http://www.enterprisemanagement.com.

Share article on social media or email:

Mount Sinai Achieves Highest Rating From Society of Thoracic Surgeons for Ground-Breaking Esophagectomy Program


“Focusing on the fine points of an operation is what actually gets rid of the cancer and helps ensure that the patient will recover without a complication,” said Dr. Raja Flores, chair of thoracic surgery at the Mount Sinai Health System.

The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS).

According to STS, only 13 institutions in the United States and Canada hold the three-star rating, which denotes the highest category of quality, for esophagectomy surgery. The esophagectomy overall performance score represents two domain scores in a single number: absence of both operative mortality and major morbidity.

Esophagectomy is the main surgical treatment for esophageal cancer. Mount Sinai’s esophagectomies incorporate a surgical innovation by Raja Flores, MD, Chair of Thoracic Surgery at the Mount Sinai Health System, who pioneered a simple yet highly effective change in the surgical approach.

“I’m surprised and honored at the recognition our department has received from the STS,” Dr. Flores said. “Surprised because it has been my hope that surgeons at other institutions would adopt our modification, which simply involves switching the juncture site between the stomach and the esophagus to promote better blood flow between the two organs.” Dr. Flores described the revision in an article in the Journal of Surgical Oncology and created a video to demonstrate the technique.

The revised procedure is less invasive than conventional esophagectomy, causes less trauma, and reduces complications such as leaking or obstruction. It also decreases the average surgical time from seven to 2.5 hours, according to the journal article.

Many esophageal cancer patients have suffered for years from heartburn and acid reflux, and deal with the symptoms by taking antacids, Dr. Flores noted. Lou Martinez, an overnight custodian for the New York court system, was among them. One night several years ago, Mr. Martinez was having dinner at work and found that the food wouldn’t go down; it stuck in his throat. Even water just sat there.

“We diagnosed him with esophageal cancer, and like many other patients, he was shocked that a common symptom like heartburn could lead to a serious condition like cancer,” Dr. Flores recalled. Mr. Martinez, one of approximately 19,000 patients diagnosed with esophageal cancer annually in the United States, underwent the revised esophagectomy several years ago and continues to do well.

What drew Dr. Flores to thoracic surgery? “Actually, thoracic surgery chose me,” he said. “I didn’t know anything about the field until I was a fourth-year surgery resident in the ‘90s. I started seeing some patients who were a little rough around the edges, who suffered from self-inflicted exposures like alcohol addiction or smoking. I treated them at a time when esophagectomy was a dreaded procedure, when patients would have complications right and left. As I treated them, I realized I really love this field.”

Incremental changes have made esophagectomy much safer and more effective since then, and Dr. Flores hopes his approach will continue to move the field forward. “It’s not about whether you use a robot or laser or some other tool,” he said. “Focusing on the fine points of an operation is what actually gets rid of the cancer and helps ensure that the patient will recover without a complication.”

The STS star rating system is one of the most sophisticated and highly regarded overall measures of quality in health care, rating the benchmarked outcomes of cardiothoracic surgery programs in the United States and Canada. The General Thoracic Surgery Database (GTSD) star ratings are derived by testing whether the participant’s composite or domain score is significantly different from the overall STS average for esophagectomy for esophageal cancer performed by GTSD participants.

STS General Thoracic Surgery Public Reporting offers a comparison of GTSD and national outcomes, demonstrating the high performance of GTSD participants. The latest analysis of data for esophageal cancer resection covers a three-year period, from July 1, 2019, to June 30, 2022, and includes 101 participants.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Upneeq® Wins “Best Eye Drop for Drooping Lids” New Beauty In 13th Annual Beauty Awards


Upneeq®, 2023 New Beauty award winner for “Best Eyedrop for Drooping Lids”

“Upneeq has proven to be a gamechanger in our field,“ said Dr. Raymond Douglas, M.D., PhD, a board-certified Aesthetic Reconstructive and Oculoplastic Specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “It can work in one or both ptotic eyes in as little as five minutes…”

RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the “Best Innovation” in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.

Over 10,000 products were submitted for the 2023 awards with 399 selected. Each winning product was proven to both effectively solve an aesthetic concern and meet rigorous testing standards by the NewBeauty editorial team along with an independent panel of key opinion leaders, top medical and industry professionals as well as advisors.

According to NewBeauty Features Editor, Tatiana Bido “Upneeq couldn’t be any easier to use.” She also called it an instant eyelid-lifter for ptosis or low-lying lids during their testing process.

“Upneeq has proven to be a gamechanger in our field,“ said Dr. Raymond Douglas, M.D., PhD, a board-certified Aesthetic Reconstructive and Oculoplastic Specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “It can work in one or both ptotic eyes in as little as five minutes giving the eyes a more open looking appearance. With the drop we see an average eyelid elevation between 1 and 2 millimeters which is truly significant.”

“We are incredibly proud to be acknowledged for a second year by NewBeauty with this prestigious award,” said Brian Markison, Chief Executive Officer of RVL Pharmaceuticals. “We are building a new market where Upneeq has been an exciting innovation for eyelids – as the first Rx treatment for low-lying lids in adults. As we continue to build the brand in the medical aesthetics field, this recognition from the industry’s leading authority is compelling and beneficial validation.”

Upneeq® received FDA approval in July 2020 and was introduced as the only non-surgical therapeutic approved for acquired ptosis (low-lying lids) in adults. First-in-class, Upneeq® is a safe and effective, fast acting, daily treatment for patients at eye care and medical aesthetic practices nationally.

In clinical trials, Upneeq® demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies. The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache. For more information and for the complete Important Safety Information, visit http://www.upneeq.com

IMPORTANT SAFETY INFORMATION

What is UPNEEQ?

UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.


What are the most common side effects of UPNEEQ?

  • The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

What should my doctor know about before prescribing me UPNEEQ?

  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.

To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit http://www.fda.gov/medwatch.

This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

About NewBeauty / NewBeauty Awards

The highly regarded industry and consumer publication, NewBeauty is published by Sandow Media. NewBeauty is the ultimate resource redefining the beauty space with its trend-driven approach to content combining authoritative experts, education and advances in industry innovation. Filled with NewBeauty editors’ trusted voices, the magazine provides an in-depth and comprehensive look at new products and breakthrough technologies with a split reputation of scientifically accurate expert-driven original reporting with ethically balanced editorial resources. NewBeauty offers a highly- curated group of winners in the annual NewBeauty Awards. Product winners of the NewBeauty Awards Seal must effectively deliver on their claims, solve aesthetic concerns, and fulfill the rigorous testing process of editors and experts.

Share article on social media or email:

SpIntellx Rebrands as PredxBio to Unlock Spatial Biology Insights with Explainable AI


PredxBio Logo

There is a critical need to lower costs and shorten the time it takes to develop cancer drugs for pharmaceutical companies, and we believe that the new PredxBio platform is uniquely poised to address these critical challenges head-on

SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio (pronounced, “pre-dix-bio”). The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space.

Oncology is the world’s largest and fastest growing therapeutic area and immunotherapies have emerged as a promising option for late-stage cancer patients over the last decade. Immune cells play a pivotal role in detecting and destroying abnormal cells, but cancer cells can sometimes completely evade or even suppress the immune response. A deeper and enhanced understanding of the spatial and temporal heterogeneity in the tumor microenvironment (TME) is needed to establish effective immunotherapy treatments. PredxBio is leading the way to deliver transformative insights into the heterogeneous TME for cancer patients, harnessing the latest advances in Spatial Biology and Explainable AI (xAI) to predict highly accurate responses to therapies.

“We are taking this critical step in our evolution as a Spatial Biology based company to reflect the exciting capabilities we have developed leveraging unbiased spatial analytics and xAI to accelerate biomarker discovery, identify novel drug targets, and design better clinical trials identifying sub-populations of response with significantly greater precision. There is a critical need to lower costs and shorten the time it takes to develop cancer drugs for pharmaceutical companies, and we believe that the new PredxBio platform is uniquely poised to address these critical challenges head-on,” said B. Dusty Majumdar, CEO of PredxBio.

The new PredxBio platform seamlessly integrates multimodal data including spatial proteomics, spatial transcriptomics and brightfield pathology to unravel the hidden circuitries of tumor microenvironment and reveal the complex network biology of cancer. The PredxBio platform performs highly scalable, xAI powered unbiased spatial analyses of multiplex immunofluorescent, mass cytometry, and transmitted light images to enable the generation of actionable insights for accelerating biomarker discovery, identifying novel drug targets and designing better clinical trials to stratify patients cohorts.By delving into organizing principles of spatial intratumor heterogeneity and the spatial relationships between different proteins/nucleotides, PredxBio is able to quantify cell-cell interactions, identify intermediate cell types and states, and automatically discover microdomains, which are repeated spatial arrangements or clusters of diverse cells within the tissue environments. Microdomains are critical to gaining a mechanistic understanding of tumor initiation, tumor progression, and response to therapy.

The PredxBio platform is designed to improve prediction accuracies and drive personalized therapeutic options for selecting optimal therapeutics based on insights into spatial tumor biology of individual patients and their potential outcomes. With the launch of the PredxBio brand, we are positioning the company in Spatial Biology with the truly unique capability of unraveling the hidden biological circuitries of cancer to predict patient outcomes with 90%+ accuracy.

About PredxBio

PredxBio is a Pittsburgh, PA-based scaling-stage company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio’s solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio’s solutions to assess treatment response in immunotherapy.

http://www.predxbio.com

Share article on social media or email:

“Heart and Science of Yoga” Physicians Conference Curriculum Proven to Reduce Burnout 23.3% and Stress 19.9%


Mark Pettus MD Lead Clinical Study Author and Conference Speaker

“AMI’s clinically proven proprietary conference curriculum is really the antidote to physician burnout and stress.” — Mark Pettus MD

With the national physician burnout rate soaring to 53%, Mark Pettus MD will announce to the 12th annual Heart and Science of Yoga Physicians Conference that its proprietary curriculum has been proven to reduce physician burnout 23.3% and stress 19.9% in a recent peer-reviewed five year clinical study. This unique comprehensive curriculum in Yoga Science as Holistic Mind/Body Medicine, to be held at the Equinox Resort and Spa in Manchester, Vermont, is accredited for 34 CMEs through the American Medical Association and, as a hybrid conference, it will be offered simultaneously in-person and live-virtual.

Conference speaker Mark Pettus, MD will once again join the faculty of The American Meditation Institute (AMI) to present lectures on the science of Epigenetics in addition to an in-depth examination of the recent Heart and Science of Yoga clinical study. Dr. Pettus MD currently serves as Medical Director of Education, Wellness and Population Health at Berkshire Health Systems, and Associate Dean of Medical Education at the University of Massachusetts Medical Center. A featured speaker on a number of nationally broadcast television and radio programs, Dr. Pettus is also the author of “The Savvy Patient” and “It’s All in Your Head: Change Your Mind, Change Your Health, & Change Your Life.”

According to Dr. Pettus, “Any physician who is confronting challenges around joy and the capacity to thrive, definitely needs to be aware of AMI’s 12th annual Physicians Conference. Cultivating experiential knowledge is really the heart of the AMI program. This curriculum definitely meets the needs of a tremendous number of caregivers who are doing amazing work, but who are struggling to maintain a sharp, creative edge. From beginning to end, this conference contains news to use.”

AMI founder and conference director and curriculum developer Leonard Perlmutter, concurs when he says, “We are in the midst of an epidemic of behavioral health challenges. When the therapeutic practices presented at this conference are consistently incorporated into the daily lives of physicians and patients, most symptoms of stress related burnout and chronic complex diseases can be diminished or eliminated.”

Previous conference graduate, Janine Pardo, MD, a Board Certified Internist and Primary Care Physician practicing in Chestnut Hill, Massachusetts positively commented, “This conference has been the most influential factor in transforming my life and medical practice. It comprehensively provides critical information, and should be a medical school requirement.”

-30-

About the American Meditation Institute

The American Meditation Institute is a 501(c)3 non-profit educational organization devoted to the teaching and practice of Yoga Science, meditation and its allied disciplines as mind/body medicine. In its holistic approach to wellness, AMI combines the healing arts of the East with the practicality of modern Western science. The American Meditation Institute offers a wide variety of courses, conferences and webinars. AMI also publishes “Transformation” a bi-monthly journal of meditation as holistic mind/body medicine. Call 518.674.8714 for a mail or email subscription.

Media Contact:

Robert Washington

PO Box 430

Averill Park, NY 12018

Tel: 518.674.8714

Fax: 518.674.8714

Share article on social media or email:

Blood Cancers Today Expands Editorial Board With Experts in MDS and Lymphoma


Blood Cancers Today, a Mashup Media LLC property, is excited to announce the addition of two new members to its Editorial Board. Effective immediately, Guillermo Garcia-Manero, MD, and Kami Maddocks, MD, join the board’s founding members, Editor-in-Chief Sagar Lonial, MD, FACP, and Associate Editors Elias Jabbour, MD; Thomas Martin, MD; Jerald Radich, MD; and Laurie Sehn, MD, MPH.

Blood Cancers Today, now in its second year of publication, is a web, email, and print platform that provides the latest news, education, and information relevant to hematologists and oncologists. It was launched in January 2022 as a partnership between Mashup Media, LLC and the Society of Hematologic Oncology (SOHO).

“I am thrilled to announce that Drs. Garcia-Manero and Maddocks have joined the Editorial Board,” Dr. Lonial said. “Their expertise in myelodysplastic syndromes (MDS) and lymphoma, respectively, will add even more depth to the content and contribute to the growth of the publication.”

SOHO noted that Dr. Garcia-Manero, of the University of Texas MD Anderson Cancer Center, currently leads the largest program in MDS in the world and has been a long-time member of SOHO.

“In addition to his clinical and translational research expertise in MDS and acute myeloid leukemia, Dr. Garcia-Manero has led the development and advancement of treatments for these diseases worldwide,” SOHO said. “He is also a long-standing member of our organization, currently serving as president-elect, and he will assume the SOHO presidency following the SOHO 2023 Annual Meeting in September.”

SOHO said that the research done by Dr. Maddocks, of the Ohio State University, research will continue to improve treatment options for patients with lymphoma.

“Dr. Maddocks currently serves on the SOHO Education Committee, lending her expertise to developing programs and content related to B-cell malignancies, non-Hodgkin lymphoma, and Hodgkin disease,” SOHO said. “Dr. Maddocks’ experience and ongoing research with novel targeted therapies in lymphoma will continue to improve treatment options for this challenging group of patients.”

“We are pleased to expand our relationship with key opinion leaders by partnering with Drs. Garcia-Manero and Maddocks. The Blood Cancers Today platform will benefit from their unique insights and perspectives, as well as their commitment to advancing the field of hematologic oncology,” said JC Landry, CEO of Mashup Media.

Visit the Blood Cancers Todaywebsite to learn more.

###

About Mashup Media, LLC

Mashup Media, based in Manalapan, NJ, is a multimedia publishing company passionate about providing health care professionals with a platform to further publicize their work. Driven by data and analytics, Mashup Media produces cutting-edge products that deliver content from trusted sources and industry thought leadership. To learn more, visit http://mashupmediallc.com/mashupmediallc.com.

About Blood Cancers Today

“Translating hematologic oncology advances into practice.”

Blood Cancers Today is a web, email, and print platform that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field, on topics such as leukemia, lymphoma, myeloma, myeloproliferative neoplasms, and other hematologic malignancies. The publication is produced in partnership with the Society of Hematologic Oncology, whose mission is to expedite worldwide research through the exchange of scientific information. Learn more at bloodcancerstoday.com.

Share article on social media or email:

Children’s Miracle Network Hospitals® Celebrates 40th Anniversary and $8 Billion Raised to Change Kids’ Health


News Image

“We remain unconditionally committed to our mission of changing kids’ health to change the future,” said Teri Nestel, President & CEO of Children’s Miracle Network Hospitals.

Hundreds of Children’s Miracle Network Hospitals partners and supporters are gathering at the Orlando World Center Marriott in Florida, April 4-7, to celebrate the network’s 40th anniversary and the more than $8 billion it’s raised for children’s hospitals across the U.S. and Canada since 1983.

Children’s Hospitals Week, presented by Ace Hardware, will introduce 10 pediatric patients, referred to by the network as champions, from the U.S. and 12 from Canada. These champions advocate for funding to change kids’ health and share, through first-hand experiences, just how vital local, unrestricted fundraising is for member hospitals of Children’s Miracle Network Hospitals to meet the needs of their communities.

Co-founders Marie Osmond, John Schneider, Mick Shannon, Joe Lake, and singer/songwriter Andy Grammer are a few of many attendees this week, along with hundreds of representatives from local member hospitals, corporate fundraising and media partners, and sponsors. In addition, gamers from across the country will compete to raise funds for their local member children’s hospital during the 9th annual Extra Life United gaming tournament.

“As we recognize the people and partners who have contributed to our success over the past 40 years, we’ll also be empowering them to take new, innovative approaches to reach more people and raise even more money to meet the health needs of kids today and challenges of tomorrow,” said Teri Nestel, President & CEO of Children’s Miracle Network Hospitals.

For 40 years, Children’s Miracle Network Hospitals has strived to change kids’ health to change the future. Since its inception in 1983, the organization has raised over $8 billion to provide funding that has helped hundreds of millions of children get the care they need from 170 member children’s hospitals across the U.S. and Canada. The nonprofit’s footprint has grown from 22 children’s hospitals in 15 U.S. states to 170 children’s hospitals that care for more than 12 million kids annually.

Children’s Miracle Network Hospitals started as a telethon, entertaining people while giving them an easy way to support the cause of kids’ health. That same spirit continues to inspire fundraising efforts today. Fundraising opportunities have evolved and are now unique to the passions of shoppers, students, gamers, golfers, families, and more.

“We remain unconditionally committed to our mission of changing kids’ health to change the future,” said Nestel, who’s been part of Children’s Miracle Network Hospitals in various roles for 34 years. “When we change the health of even one child, we create a ripple effect that benefits communities of people for years to come.”

Nestel adds that this mission is more critical than ever because of the challenges facing children’s hospitals. “The health needs of children continue to grow and change – and we’ve lost some ground because of the COVID-19 pandemic and its after-effects,” said Nestel.

Children’s Hospitals Week is presented by Ace Hardware and supported by these generous partners: Marriott International, Inc., Panda Restaurant Group, Inc., 7-Eleven, Inc., Marriott Vacations Worldwide, Love’s Travel Stops, The Brick, Air Canada Foundation, and Knight-Swift Transportation. For more information on Children’s Miracle Network Hospitals and how to support the local Children’s Miracle Network Hospital in your area, go to cmnhospitals.org.

About Children’s Miracle Network Hospitals:

Children’s Miracle Network Hospitals® raises funds for 170 children’s hospitals supporting the health of 12 million kids annually across the U.S. and Canada. Donations go to local hospitals to fund critical life-saving treatments and healthcare services, along with innovative research, vital pediatric medical equipment, child life services that put kids’ and families’ minds at ease during difficult hospital stays and financial assistance for families who could not otherwise afford these health services. When we improve the health of all children and allow them the opportunity to reach their full potential, we also improve our communities for years to come. Together, we can change kids’ health. Together, we can change the future. To learn about Children’s Miracle Network Hospitals and your local children’s hospital, visit cmnhospitals.org.

Share article on social media or email:

Spinal Resources Inc. Unveils Groundbreaking Spine Platform for Improved Patient Care


Spinal Resources Inc leading innovator in spinal technology announced FDA-approval of Solutions Based Spine Platform Bezier Rod

Spinal Resources Inc. (SRI), a leading innovator in spinal technology, has announced the FDA-approval of its state-of-the-art, Solutions Based Spine Platform (SBSP). The unique platform is designed to provide surgeons with an unparalleled solution to address and assist in the reduction of critical spinal conditions like Proximal Junctional Kyphosis (PJK), Proximal Junctional Failure (PJF), and Adjacent Segment Disease (ASD).

The Solutions Based Spine Platform features a novel screw cap interface that toggles between a polyaxial and monoaxial head. This unique mechanism allows for free translation of the rod, facilitating screw head manipulation, compression, distraction, and coronal de-rotation. “We are thrilled about the FDA-approval of our Solutions Based Spine Platform as it is a testament to our commitment to innovation and bringing spinal care forward,” said Bernard M. Bedor, Founder, President, and CEO of Spinal Resources Inc.

“In complex adult spinal surgery, the complications of non-union/rod fracture and proximal junctional failure (PJF) remain significant concerns, often driving revision surgery within the first year or two of an index operation. In some ways, these complications also counterbalance each other. Rod fracture is delayed or reduced by increasing the stiffness of the posterior rod construct. On the other hand, increased construct stiffness at the proximal junction can only increase the incidence of PJF'” said Dr. Robert Hart, Medical Director for Spinal Deformity at the Swedish Neuroscience Institute. “Creating a rod that is stronger at the caudal end of the construct but of reduced stiffness at the cranial end would be ideal. While there are several design approaches to addressing this concern, none are currently optimal. Specifically, short tapers in rod diameter are problematic. For one thing, they create a stress riser at the junction from larger to smaller diameter rods, increasing potential for rod failure. Further, they are difficult to contour as traditional rod bending tools accentuate curvature within the smaller diameter portion as opposed to the stiffer, larger diameter portion of the rod.”

Additional features of the system include:

  • A range of Bezier Taper transition rods (4.75, 5.0, 5.5, 6.0), ( 4.75,5.0, 5.5) ( 5.0, 5.5, 6.0)
  • A unique blend of curved Morphotypes that have been developed from post-operative data with seamless transitions between linear segments
  • A Swedge pedicle Screw and Locking Cap system that allows for the use of the entire rod, including the tapered segments, providing flexibility intraoperatively.
  • Allows surgeons to tailor individual rod diameters to bone quality (individual diameters of 4.75, 5.0, 5.5, and 6.0 can be used alone in the same head and same locking cap allowing the reduction of micromotion and stress shielding which can lead to implant loosening
  • The Bezier Rod applies to Deformity and Degenerative surgeons allowing for a synergistic pathway between the two. The Bezier rod platform will have shorter-length rods allowing the technology to be used across several disciplines.


“This is a rod system that enhances the physiology of spinal fusion with respect to stress and strain rather than the stress shielding that occurs with larger diameter rods. The gradual taper accommodates the differing physiological needs to optimize stress and strain at all levels of the construct promoting solid fusion and providing a proximal soft landing to reduce the formation of a stress riser,” said Dr. Roland Kent, fellowship-trained Spine Surgeon and the co-founder of Axis Spine Center.

SRI is also developing an AI platform that will have the ability to the forces and loads on adjacent segments based on the in-situ functioning of the Bezier Rod and Bezier Rod Morphotype system. This innovative feature will provide valuable insights into the performance of the rods, cap, and screw interface, enabling a better understanding of the forces unloaded at the adjacent segment and the potential occurrence of failure at the adjacent segment. The platform offers a robust, biomechanically sound, and innovative approach to spinal care, leveraging our unique rod system and cutting-edge AI technology.

“The SRI system represents a significant advancement in the technology available in my surgical armamentarium. It allows for an array of interoperative choices based upon patient bone density, segment, and mobility of the spine. This provides intraoperative flexibility, using multiple rod diameters which allows surgeons to tailor patient-focused rods and solutions. This is seamlessly achieved by customizing the linear segments and transitions and controlling the flex of the rod. The result is a more even distribution of forces across the construct, unloading the proximal and distal segments” said Dr. Hamid Hassanzadeh, Chief of Orthopaedic Surgery at Johns Hopkins.

For more information about Spinal Resources Inc. and its Solutions Based Spine Platform, please visit http://spinalresourcesinc.com/ or contact the media relations team.

About Spinal Resources, Inc.

Spinal Resources, Inc. (SRI) is a Florida-based spinal medical device company that provides innovative mechanical and biomechanical products to support cost-effective patient care, alleviate pain, shorten recovery time, restore health, and extend quality of life. SRI has engineered a unique line of patented open, reduction, and minimally-invasive spinal systems for the surgical repair and reconstruction of debilitating spinal conditions. With a focus on innovation, SRI is committed to developing groundbreaking technologies that address critical spinal conditions.

Share article on social media or email:

New toilets benefit students; Project made possible through donor funding from Salesian Missions.


News Image

St. John Paul II School in the community of Maram Khullen, located Manipur, India, has a new toilet complex thanks to donor funding from Salesian Missions, the U.S. development arm of the Salesians of Don Bosco.

The project is part of the Salesian Missions “Clean Water Initiative.” The school provides education to 170 students, ages 4-13, with the support of 10 staff members.

The funding was utilized for construction of the entire complex from the foundation to the ceiling and walls. Funding was also used to tile the floor, paint the entire building, and install the toilets and partition them. Separate areas of the building were provided for both boys and girls.

Father Sebastian Chennoth, who is in charge of the school, said, “The whole school will benefit from the toilet complex. It is especially true for the girls in the higher classes. It was not easy for them prior to the new complex. This was more embarrassing when some were sick or had stomach troubles. A few students even used to run to the neighboring houses for their needs.”

Houdina, a girl in class 7, expressed her gratitude for the new toilet complex. “I am very happy now. I don’t feel embarrassed anymore. I never went during school recess to the toilet, but used to go during class time to avoid the gaze of the boys.”

With more than 1.4 billion people, India’s growing population is putting a severe strain on the country’s natural resources. According to Water.org, 91 million people lack access to safe water, and 746 million people lack access to safely managed household sanitation facilities.

While India has made some progress in the supply of safe water, there remain gross disparities in safe water access across the country. The World Bank estimates that 21 percent of communicable diseases in India are related to unsafe water with diarrhea alone causing more than 1,600 deaths daily. Access to proper sanitation is extremely poor, particularly in rural areas where only 14 percent of the population has access to a latrine.

###

About Salesian Missions USA

Salesian Missions is headquartered in New Rochelle, NY, and is part of the Don Bosco Network—a worldwide federation of Salesian NGOs. The mission of the U.S.-based nonprofit Catholic organization is to raise funds for international programs that serve youth and families in poor communities around the globe. The Salesian missionaries are made up of priests, brothers and sisters, as well as laypeople—all dedicated to caring for poor children throughout the world in more than 130 countries and helping young people become self-sufficient by learning a trade that will help them gain employment. To date, more than 3 million youth have received services funded by Salesian Missions. These services and programs are provided to children regardless of race or religion. For more information, go to SalesianMissions.org.

Contact:

Laura Perillo

media@salesianmissions.org

908-406-3413 (text messages OK)

Twitter: @MissionNewswire

Newswire: MissionNewswire.org

Press room: SalesianMissions.org/press

Share article on social media or email:



NDA Partners Appoints Senior Global Regulatory Affairs Executive, Dr. Daniela Drago as Partner in the Firm


News Image

Dr. Drago’s expertise in global regulatory and product development has been highly valued by our clients, and her leadership as Partner in the firm will play a critical role as we expand the services and regulatory support that we offer our clients.

NDA Partners’ Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm. Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.

Dr. Drago is a CMC and global regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles. She has significant global expertise in the development of small molecules, biologics, cell and gene therapies, and combination products in multiple rare and common disease areas, including ophthalmology, neurology, immunology, and oncology. According to Dr. Carl Peck, Manager of the NDA Partners’ drug development practice, “Dr. Drago’s expertise in global regulatory and product development has been highly valued by our clients, and her leadership as Partner in the firm will play a critical role as we expand the services and regulatory support that we offer our clients.”

Dr. Drago formerly served as Associate Professor at George Washington University’s School of Medicine. She currently serves as Adjunct Faculty for the University of California, San Francisco (UCSF), American Course on Drug Development and Regulatory Sciences (ACDRS), and the University of Basel, European Center of Pharmaceutical Medicine (ECPM). She serves on the Board of Directors of the Regulatory Affairs Professional Society (RAPS), the Regulatory Affairs Committee of the American Society of Gene and Cell Therapy (ASGCT), and the Executive Committee of ACDRS.

Dr. Drago received her PhD in Chemistry from the Swiss Federal Institute of Technology (ETH) in Zurich and MS in Chemistry from the University of Messina in Italy. She is a TOPRA Fellow (FTOPRA) and a Fellow of the Regulatory Affairs Professional Society (FRAPS). She has received several awards, including the TOPRA Award for Regulatory Excellence and the RAPS Community Leadership Award.

About NDA Partners

NDA Partners, a ProPharma company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, Vice President & General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email: